Bone Marrow Research

Clinical Study

Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors

Table 7

Influence of MiHA mismatches on allo-HCT outcomes.


Analyzed outcome	Analyzed MiHA	Direction of mismatch	Presence of mismatch		Probability (95% CI)

Overall survival	Autosomal	GVH	Yes	15	2 yrs: 0.9286 (0.5278–0.9892)	0.045
					4 yrs: 0.7619 (0.3481–0.9130)
			No	47	2 yrs: 0.6046 (0.4329–0.7243)
					4 yrs: 0.5265 (0.3511–0.6545)
	HY	GVH	Yes	12	2 years: 0.4167 (0.0590–0.6384)	0.011
					3 years: 0.3333 (0.0054–0.5532)
			No	50	2 years: 0.7546 (0.5986–0.8500)
					3 years: 0.6822 (0.5152–0.7916)

Disease-free survival	HY	GVH	Yes	12	2 years: 0.4167 (0.0590–0.6384)	0.050
					3 years: 0.3333 (0.0054–0.5532)
			No	50	2 years: 0.6526 (0.4896–0.7635)
					3 years: 0.6526 (0.4896–0.7635)

Serious aGVHD	HY	GVH	Yes	12	0.1667 (0.0470–0.5906)	0.037
			No	50	0.0200 (0.0029–0.1392)

Extensive cGVHD	HY	GVH	Yes	11	0.3636 (0.1664–0.7947)	0.017
			No	43	0.1395 (0.0664–0.2931)

Relapse	Autosomal	HVG	Yes	12	0 (0-0)	0.032
			No	50	0.2836 (0.1818–0.4423)
	Restricted	HVG	Yes	13	0 (0-0)	0.028
			No	49	0.2879 (0.1849-0.4482)